Cargando…

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide

Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder characterized by ineffective hematopoiesis. It is characterized by peripheral blood cytopenia and significant risk of progression to acute myeloid leukemia result. Deletion of the long arm of chromosome 20 (20q deletion) is present in 3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jana, Bagi, Khanfar, Anas, Ninan, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970358/ https://www.ncbi.nlm.nih.gov/pubmed/24716056 http://dx.doi.org/10.1155/2014/949515

Ejemplares similares

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion
por: YANG, YAN, et al.
Publicado: (2013)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
por: Lee, Dawn, et al.
Publicado: (2018)

Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
por: Uno, Shuji, et al.
Publicado: (2023)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
por: Hecht, Anna, et al.
Publicado: (2021)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
por: Koh, Yu Han, et al.
Publicado: (2023)

Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
por: Ohyashiki, Kazuma, et al.
Publicado: (1989)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
por: Sugimoto, Yuka, et al.
Publicado: (2012)

Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome Associated with Deletion of Chromosome 20q
por: Manthri, Sukesh, et al.
Publicado: (2018)

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center
por: Narayanan, Santhosh
Publicado: (2017)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Cytogenetic features in myelodysplastic syndromes
por: Haase, Detlef
Publicado: (2008)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis
por: Lian, Xin-yue, et al.
Publicado: (2016)

Rare Cytogenetic Abnormalities in Myelodysplastic Syndromes
por: Bacher, Ulrike, et al.
Publicado: (2015)

Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
por: Zahid, Mohammad Faizan, et al.
Publicado: (2017)

Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
por: Hong, Junshik, et al.
Publicado: (2021)

Clinical, Hematological, and Cytogenetic Profile of Myelodysplastic Syndromes in Adults: A Three-year Cross-sectional Study
por: Abraham, Latha, et al.
Publicado: (2023)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
por: Burgos, Sebastian, et al.
Publicado: (2019)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

Mechanism of action of lenalidomide in hematological malignancies
por: Kotla, Venumadhav, et al.
Publicado: (2009)

Expanding role of lenalidomide in hematologic malignancies
por: Ghosh, Nilanjan, et al.
Publicado: (2015)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
por: Al-Jafar, Hassan A., et al.
Publicado: (2012)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients
por: Paridar, Mostafa, et al.
Publicado: (2021)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q
por: Park, Isaac, et al.
Publicado: (2021)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities
por: L’Abbate, Alberto, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f4sf0uhu13jb4g0ma16njh3hia